alexa A Four-Drug Induction Therapy Including Raltegravir for
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A Four-Drug Induction Therapy Including Raltegravir for the Treatment of Naïve HIV-Infected Patients

Katia Falasca1*, Claudio Ucciferri1,2, Marta Di Nicola3, Francesca Vignale1, Delia Racciatti1 and Jacopo Vecchiet1

1Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Italy

2Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy

3Laboratory of Biostatistics, Department of Experimental and Clinical Sciences, University “G. d’Annunzio” Chieti-Pescara, Italy

Corresponding Author:
Prof. Katia Falasca
Clinic of Infectious Diseases
Dept. of Medicine and Science of Aging
“G. d’Annunzio” University, School of Medicine
Via dei Vestini, 66013 Chieti, Italy
Tel: +39 0871 357582
Fax: +39 0871 358595
E-mail: [email protected]

Received date: June 20, 2017; Accepted date: June 24, 2017; Published date: June 29, 2017

Citation: Falasca K, Ucciferri C, Nicola MD, Vignale F, Racciatti D, et al. (2017) A Four-Drug Induction Therapy Including Raltegravir for the Treatment of Naïve HIV-Infected Patients. J AIDS Clin Res 8:705. doi:10.4172/2155-6113.1000705

Copyright: © 2017 Falasca K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Despite the recent advances in antiretroviral therapy, human immunodeficiency virus type 1 (HIV-1) remains a global health threat. The aim of this study was evaluated the efficacy of a four-drug induction antiretroviral therapy (ART), including raltegravir (RAL), on the rapidity of suppression of plasma HIV-RNA below detectable concentrations and its impact on immunological recovery. Methods: In this single centre, randomized prospective trial, 32 naïve HIV+ patients at the same clinical stage were enrolled and randomized for baseline viral load: sixteen subjects started ART with four antiretroviral drugs including RAL, while the remaining patients started the same therapy without RAL. Viro-immunological and metabolic parameters, indexes of hepatic and renal functionality were measured at baseline (T0) and after three (T3), six (T6) and twelve months (T12) from therapy introduction. Results: We observed a faster viral drop in the group under RAL-therapy with respect to the other group. At the first month (T1) of therapy, the HIV-RNA was significantly lower in the patients receiving RAL-therapy (p<0.05). Immunological recovery was higher in patients with RAL than in those on other therapy at all detection times, with a significant increase at T3, T6 and T12 (p=0.02). Conclusion: In this study, we found, for the first time, a rapid and significant improvement in CD4+ T cells count in patients with four drug induction therapies. The four-drug regimen was safe, well tolerated and also associated with a rapid decay of plasma HIV-RNA levels.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords